b. Bone marrow (CP) IM sensitive c. Bone marrow (CP) IM resistant

Slides:

Advertisements

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Advertisements

CML- Imatinib Mesylate (Gleevec™) Philadelphia Chromosome Short chromosome 22 Bcr region of chromosome 22 with Abl proto-oncogene of chromosome 9.

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.

LEUKEMIA—HEMATOLOGY {S1}

Fig. 16-CO, p Fig. 16-1, p. 450 Fig. 16-2, p. 450.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Low-power scanning electron microscope image of normal bone architecture in the 3 rd lumbar vertebra of a 30 year old woman marrow and other cells removed.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Phase Difference = Phase Difference = 0.05.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

In what phase is cell #1?. Name this part of the microscope.

Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis.

How do organs work together? Organs work together in organ systems to carry out major life functions.

Hematopoietic Cancers Common Disruptions

The reading is 7.38 mm. The reading is 7.72 mm.

Lesson objectives To name the three types of blood cells

(a) (b) Up-regulated in R Down-regulated in R Up-regulated in S

Figure 1. A B C D E F Survival proability (%) Bone marrow blast count

CHRONIC MYELOID LEUKEMIA (CML)

Resistance in the land of molecular cancer therapeutics

Fig. 1. TP is highly expressed in myeloma.

Bone remodeling Lining cells Bone marrow.

تحليل الحساسية Sensitive Analysis.

Chronic Leukemia Kristine Krafts, M.D..

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

(6h ) Supplemental Fig. 2 a. 32Dp210 b. 32Dp210 c. 32DP210

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

חקרשת webquest לכיתה ה2 , בי"ס "צהלה"

Volume 14, Issue 3, Pages (September 2008)

Volume 8, Issue 5, Pages (November 2005)

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

,. . ' ;; '.. I I tI I t : /..: /.. ' : ····t I 'h I.;.; '..'.. I ' :".:".

* * * A B D C E CP110 Tubulin WB: CP110 WB: HA CP110 KRAS Tubulin

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

Supplemental Figure 1 a b c d.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Suppl. Fig. 2 A B Evaluation of FasL-induced apoptosis in BM-MSCs.

Mast cell activation syndrome: Proposed diagnostic criteria

Cycling toward Elimination of Leukemic Stem Cells

Case study 14 Hadeel , Huda , Abeer.

Name that bone....

Supplemental Figure 1A SMM Patient #1 MP-CTL % CD3+ CD8+ T Cells

Human granulocyte-macrophage colony-stimulating factor (hGM-CSF)–dependent in vitro and in vivo proliferation and differentiation of all hematopoietic.

Matthew P. Strout, David G. Schatz Cancer Cell

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

TC-1 silencing sensitized A549 and SPC-A-1 cells to radiation therapy

Fig. 1. Morphological and growth characterization of hBMCs and hPDCs

Presence of EGFP+ cells, CD11b+ cells and LCA+ cells in the thyroid of EGFP+ → EGFP– bone marrow radiation chimeras (week 3). Presence of EGFP+ cells,

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Induction of apoptosis by nelfinavir and bortezomib

Supplemental Fig 1 (A) (B) (B) 59% % alive 52% Years from entry 59%

Fig. 8. Functional assays revealed that ALD increases the K+ efflux of NKCC1. The functionality of NKCC1 activity was analyzed in individual cells using.

Acute Megakaryocytic Leukemia

Volume 14, Issue 3, Pages (September 2008)

Figure 5. Hematopoietic cell specific Atg5 deficiency results in aberrant proliferation and mitochondrial dysfunction in hematopoietic cells. (A) Apoptosis.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Fig. 2. Scriptaid and RGFP966 alter macrophage phenotype

Жаңа ақпараттық оқыту технологиясы

Suppl. Fig. 1A - - fraction Suppl. Fig. 1B - - fraction

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Presentation transcript:

b. Bone marrow (CP) IM sensitive c. Bone marrow (CP) IM resistant Supplemental Fig. 4 b. Bone marrow (CP) IM sensitive Bone marrow (CP) IM sensitive 20 40 60 80 100 120 C IM-10 TG-5 TG-10 (mM) Apoptosis (%) 10 20 30 40 50 60 70 C IM-5 IM-10 TG-2.5 TG-5 Apoptosis (%) (mM) c. Bone marrow (CP) IM resistant 100 80 60 40 20 C IM-5 IM-10 TG-1.0 TG-2.0 TG-4.0 TG-5.0 Inhibitors (M) Apoptosis (%) CD34+ (Blast Crisis) a. Bone marrow (CP), IM resistant 15 30 45 60 75 90 C IM-10 TG-2.5 TG-5 TG-10 Apoptosis (%) (mM) d. Bone marrow (CP) IM resistant e. CD34+(accel. phase) 20 40 60 80 100 C IM-10 TG -10 WP-5.0 (mM) Apoptosis(%) f. Baf3-T315I cell line C IM-5 IM-10 TG-1.0 TG-2.5 TG-5.0 TG-7.5 TG-10 Imatinib / TG101209 (M) 120 100 80 60 40 20 Apoptosis (%)